跳至主要内容
临床试验/NCT06810687
NCT06810687招募中不适用

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling As Effective As Antibiotic Prophylaxis? a Randomized Controlled Trial

Atlantic Health System1 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2025年1月30日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
190
试验地点
1
主要终点
Incidence of urinary tract infection

研究概览

简要总结

Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%.

Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI.

The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.

详细描述

Synthetic polypropylene mid-urethral slings (MUS) are the gold standard for treatment of stress urinary incontinence (SUI). The most common post-operative complications are urinary tract infection (UTI), bladder injury, bleeding, and mesh erosion. Amongst these complications, post-operative urinary tract infections are the most common complication with incidences up to 21-34%. With high incidences in post-operative UTI, previous studies have shown evidence for the use of prophylactic antibiotics after MUS placement. Previous studies have demonstrated prophylactic antibiotics after MUS placement decreased the incidence of post-operative UTI in the treated groups. While the use of post-operative prophylactic antibiotics may decrease the risk of post-operative UTI, it is essential to consider the broader implication of such antibiotic use.

Along with increased antibiotic use, there is an increase in multidrug resistant uropathogens. This has led to an increased emphasis on antibiotic stewardship to optimize patient care by minimizing the risk of developing antibiotic resistant organisms, preserving effectiveness of currently used antibiotics, and promoting appropriate prescribing practices. There are no studies evaluating post-operative UTI prophylaxis after MUS with methenamine.

Methenamine is a urinary antiseptic that acts when methenamine is converted to ammonia and formaldehyde, which denatures bacterial proteins and nucleic acids. There is no evidence of bacterial resistance to methenamine. Methenamine has been shown to be non-inferior to antibiotic prophylaxis in the setting of recurrent UTI. Methenamine has most commonly been used as long-term UTI prophylaxis treatment, but there are studies demonstrating benefit from short-term methenamine use for prophylaxis.

The investigator's aim is to evaluate whether methenamine is non-inferior to antibiotic prophylaxis after MUS procedure in preventing post-operative UTI.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients undergoing mid-urethral sling procedure

排除标准

  • Medication intolerance or allergy to study medications
  • Renal impairment with GFR <30
  • Breast feeding
  • Recurrent urinary tract infections
  • Active urinary tract infection
  • Immunosuppressive disease
  • Interstitial cystitis

研究组 & 干预措施

Methenamine prophylaxis

Experimental

Methenamine will be prescribed for urinary tract infection prophylaxis

干预措施: Methenamine Hippurate 1g BD (Drug)

Antibiotic prophylaxis

Active Comparator

Antibiotic prophylaxis chosen per physician preference

干预措施: Antibiotic prophylaxis (Other)

结局指标

主要结局

Incidence of urinary tract infection

时间窗: Within 6 weeks after the procedure

Urinary tract infection (Positive urine culture) within 6 weeks post-operatively after completing 3 days of antibiotics or methenamine

次要结局

  • Number of participants with adverse effects(within 6 weeks after the procedure)
  • Occurrence of additional treatment of UTI(Within 6 weeks after the procedure)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shaun Adair

MD

Atlantic Health System

研究点 (1)

Loading locations...

相似试验